Диссертация (1174220), страница 44
Текст из файла (страница 44)
– 2016. - 22(6). - Р. 810-816.177. Hobart J.C., Riazi A., Lamping D.L. et al. Improving the evaluation of therapeutic interventionsin multiple sclerosis: development of a patient-based measure of outcome. // Health TechnolAssess – 2004. - 8(9). - iii, 1-48.178.
Hojati Z. Molecular Genetic and Epigenetic Basis of Multiple Sclerosis. // Adv Exp Med Biol. –2017. – 958. - Р. 65-90.179. Hollenbach J.A., Oksenberg J.R. The Immunogenetics of Multiple Sclerosis: A ComprehensiveReview. // J Autoimmun. – 2015. – 64. - Р. 13–25.184180. Howard J, Trevick S., Younger D.S. Epidemiology of Multiple Sclerosis. // Neurol Clin. – 2016.- 34(4). - Р. 919-939.181. Hu X., Miller L, Richman S. et al. A novel PEGylated interferon beta-1a for multiple sclerosis:safety, pharmacology, and biology. // J Clin Pharmacol.
– 2012. – 52. - Р. 798-808.182. Hutchinson M., Kappos L., Calabresi P. et al. The efficacy of natalizumab in patients withrelapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. // J Neurol – 2009.– 256. - Р. 405–415.183. Ingwersen J., Aktas O., Kuery P. et al. Fingolimod in multiple sclerosis: Mechanisms of actionand clinical efficacy.
// Clin Immunol. – 2012. – 142. - Р. 15-24.184. Jacobs L.D., Cookfair D.L., Rudick R.A. et al. The Multiple Sclerosis Collaborative ResearchGroup. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. //Ann Neurol. – 1996.
- 39(3). - Р. 285-294.185. Janssens A.C., van Doorn P.A., de Boer J.B. et al. Impact of recently diagnosed multiplesclerosis on quality of life, anxiety, depression and distress of patients and partners. // ActaNeurol Scand. – 2003.
- 108(6). - Р. 389-395.186. Johnson K.P., Brooks B.R., Cohen J.A. et al. Copolymer 1 reduces relapse rate and improvesdisability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, doubleblind placebo-controlled trial. // Neurology.
– 1995. – 45. - Р. 1268-1276.187. Johnson K.P., Brooks B.R., Cohen J.A. et al. Extended use of glatiramer acetate (Copaxone) iswell tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree ofdisability. Copolymer 1 Multiple Sclerosis Study Group. // Neurology. – 1998. – 50.
- Р. 701708.188. Johnson K.P., Ford C.C., Lisak R.P., Wolinsky J.S. Neurologic consequence of delayingglatiramer acetate therapy for multiple sclerosis: 8-year data. // Acta Neurol Scand. – 2005. –111. - Р. 42-47.189. Jongen P.J., Lehnick D., Sanders E. et al. Health-related quality of life in relapsing remittingmultiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational,international, multi-centre study. // Health Qual Life Outcomes.
– 2010. – 8. - Р. 133.190. Jongen P.J., Sindic C., Carton H. et al. Functional composite and quality of Life in Avonextreated Relapsing multiple sclerosis patients study group. // J Neurol.- 2010. - 257(4). - Р. 584589.191. Julian L.J, Vella L., Frankel D. et al. ApoE alleles, depression and positive affect in multiplesclerosis. // Mult Scler - 2009. – 15. - Р.
311-315.185192. Kappos L., Bates D, Hartung H.P. et al. Natalizumab treatment for multiple sclerosis:recommendations for patient selection and monitoring. // Lancet Neurol – 2007. – 6. - Р. 431441.193. Kappos L., Kuhle J., Multanen J. et al. Factors influencing long-term outcomes in relapsingremitting multiple sclerosis: PRISMS-15.
// J Neurol Neurosurg Psychiatry. – 2015. - 86(11). - Р.1202-1207.194. Kappos L., Gold R., Miller D. et al. Efficacy and safety of oral fumarate in patients withrelapsing–remitting multiple sclerosis: a multicenter, randomized, double-blind, placebocontrolled phase IIb study. // Lancet. – 2008. – 372. - Р. 1463–1472.195. Kappos L., Radue E., O‘Connor P.
et al. A placebo-controlled trial of oral fingolimod inrelapsing multiple sclerosis. // N Engl J Med – 2010. – 362. - Р. 387–401.196. Karussis D., Biermann L. D., Bohlega S. et al A recommended treatment algorithm in relapsingmultiple sclerosis: report of аn international consensus meeting. // Europ J Neurology. – 2006. –13.
- Р. 61–71.197. Kempen G.I. The MOS Short-Form General Health Survey: single item vs multiple measures ofhealth-related quality of life: some nuances. // Psychol Rep. – 1992. - 70(2). - Р. 608-610.198. Khan F., Pallant J. Chronic pain in multiple sclerosis: prevalence, characteristics, and impact onquality of life in an Australian community cohort. // J Pain. – 2007. - 8(8).
- Р. 614-623.199. Khan U.T, Tanasescu R., Constantinescu C.S. PEGylated IFNβ-1a in the treatment of multiplesclerosis. // Expert Opin Biol Ther. – 2015. - 15(7). - Р. 1077-1084.200. Kieseier B.C., Calabresi P.A. PEGylation of interferon-β-1a: a promising strategy in multiplesclerosis. // CNS Drugs. – 2012. – 26.
- Р. 205-214.201. Kingwell E., Marriott J.J., Jetté N. et al. Incidence and prevalence of multiple sclerosis inEurope: a systematic review. // BMC Neurol. – 2013. – 13. - Р. 128.202. Kiselev I., Bashinskaya V., Kulakova O. et al. Variants of MicroRNA Genes: Gender-SpecificAssociations with Multiple Sclerosis Risk and Severity. // Int J Mol Sci.- 2015. - 16(8). - Р.20067-20081.203.
Kita M., Fox R.J., Phillips J.T. et al. Effects of BG-12 (dimethyl fumarate) on health-relatedquality of life in patients with relapsing-remitting multiple sclerosis: findings from theCONFIRM study. // Mult Scler. – 2014. - 20(2). - Р. 253-257.204. Kita M.
FDA-approved preventative therapies for MS: first-line agents. // Neurol Clin. – 2011. 29(2). - Р. 401-409.205. Kleinschmidt-Demasters B.K., Tyler K.L. Progressive multifocal leukoencephalopathycomplicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. // N EnglJ Med – 2005. – 353. - Р. 369-374.186206. Kobelt G., Lindgren P., Smala A.
et al. Costs and quality of life in multiple sclerosis. Anobservational study in Germany. // HEPAC – 2001. – 2. - Р. 60- 68.207. Kobelt G. Health economic issues in MS. // Int MS J - 2006а. – 13. - 17–26.16.208. Kobelt G., Berg J., Lindgren P. et al. Costs and quality of life of patients with multiple sclerosisin Europe. // J Neurol Neurosurg Psychiatry. - 2006б. – 77.
- Р. 918–926.209. Kobelt G. Health economics: An introduction to economic evaluation. // 3rd ed. London: Officeof Health Economics. - 2013.210. Kobelt G., Thompson A., Gannedahl M. et al. New insights into the burden and costs of multiplesclerosis in Europe. // Mult Scler – 2017. - 23(8). - Р. 1123–1136.211. Kos D., Kerckhofs E., Carrea I. et al. Evaluation of the Modified Fatigue Impact Scale in fourdifferent European countries. // Mult Scler. – 2005. – 11.
- Р. 76–80.212. Kovarik P., Sauer I., Schaljo B. Molecular mechanisms of the anti-inflammatory functions ofinterferons. // Immunobiology. – 2007. – 212. - Р. 895-901.213. Kulakova O.G., Tsareva E.Y., Lvovs D., Favorov A.V., Boyko A.N., Favorova O.O.Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate. //Pharmacogenomics. – 2014. - 15(5). - Р. 679-685.214. Kurne A., Oguz K.K., Oz Aksu A.
et al. Magnetic resonance imaging at first episode in pediatricmultiple sclerosis retrospective evaluation according to KIDMUS and lesion dissemination inspace criteria. // Brain Dev. – 2010. - 32(6). - Р. 487-494.215. Kurtzke J.F. Rating neurological impairment in multiple sclerosis: an expanded disability statusscale (EDSS). // Neurology - 1983. – 33. - Р. 1444-1452.216. La Mantia L., Di Pietrantonj C., Rovaris M. et al. Interferons-beta versus glatiramer acetate forrelapsing-remitting multiple sclerosis. Cochrane Database Syst Rev.
- 2014 Jul 26. - (7). CD009333.217. Langer-Gould A., Steinman L. Progressive multifocal leukoencephalopathy and multiplesclerosis: lessons from natalizumab. // Curr Neurol Neurosci Rep. – 2006. – 6. - Р. 253-258.218. Langer-Gould A., Wu J., Lucas R. et al. Epstein-Barr virus, cytomegalovirus, and multiplesclerosis susceptibility: A multiethnic study. // Neurology. – 2017. - 89(13). - Р.
1330-1337.219. Lantéri-Minet M., Duru G., Mudge M. et al Quality of life impairment, disability and economicburden associated with chronic daily headache, focusing on chronic migraine with or withoutmedication overuse: a systematic review. // Cephalalgia - 2011.
– 31. - Р. 837–850.220. Lauer K. Environmental risk factors in multiple sclerosis. // Expert Rev Neurother. – 2010. – 10.- Р. 421-440.221. Lee Mortensen G., Rasmussen P.V. The impact of quality of life on treatment preferences inmultiple sclerosis patients. // Patient Prefer Adherence. – 2017.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
